The aim of this study was to develop a novel therapeutic method for improving immune system regulation in SLE using escalating dose self-antigen dsDNA immunotherapy. Methods: Female Balb/c mice were given a single intraperitoneal injection of 0.5 ml pristane.. Starting at 12 weeks after injection,. the mice were evaluated for clinical and serological manifestations. Mice with lupus signs (PIL mice) were divided into four groups; positive control group, PIL A (0.01 μg/ml, 0.1 μg/ml, 1 μg/ml ) EDI dsDNA, PIL B (0.1 μg/ml, 1 μg/ml, 10 μg/ml ) EDI dsDNA, and PIL C(1 μg/ml, 10 μg/ml, 100 μg/ml). EDI dsDNA were administered once every week in consecutively. The doses would increase every week. dsDNA were complexed with the cationic polyethylenimine (PEI) before injection.
INTRODUCTION
Systemic Lupus Erythematosus (SLE) is an autoimmune disease multi-systemic connective tissue inflammatory disease with high mortality and morbidity (Kessenbrock et al., 2009) .
Previous research at dr. Saiful Anwar Hospital
Malang reported that SLE patient life expectancy is very low with severe clinical manifestations (Kalim, 1996) . This proves that SLE is a dangerous disease and quite common in Indonesia. In addition, the disease is often suffered by women of reproductive age and most of the women has decreased productivity and ability to perform daily activities.
The pathogenesis of SLE is not clearly known until now, but it has been known that the presence of abnormalities of the immune system is caused by a disruption of T-regulator cell function (Treg) in regulating the immune response and this has an impact on hyperactivation of various helper T cells (Th).
Th cells, such as Th1, Th2, and Th17, will be activated by dendritic cells (DC) or other APC cells and stimulates inflammatory. Dendritic cells can recognize different types of self antigen, especially dsDNA which has an important role in the pathogenesis of SLE, and through activation of B cells will stimulate the formation of antibodies against self-antigen dsDNA. The presence of these pathogenic autoantibodies will result in tissue damage due to immune complex deposition. In addition, various cytokines such as IL-1, IL-6, IFNγ and IL-17 that act as inflammatory mediators were increased, whereas anti-inflammatory cytokines such as TGF-β and IL-10 were decreased. This cytokine imbalance plays a significant role in the pathogenesis of SLE (Pathak and Mohan, 2011). SLE standard therapy which is the administration of immunosuppressant and steroid medications have not shown satisfactory results. Furthermore, steroid administration for long period of time may cause many problems in SLE patients (Pathak and Mohan, 2011) .
Another method of therapy that is now also being developed for autoimmune patients is the administration of vaccines. A previous study by Uyttenhove (Uyttenhove and Snick, 2006) showed that by administering 10 μg of IL-17A kinoid vaccine conjugated to OVA was able to induce protective antibodies against IL-17A in autoimmune encephalitis. The anti-IL-17A antibody was also shown to induce significant neutralization of IL-17A cytokines. Research on the use of IL-17A kinoid vaccine in Lupus model mice previously performed by Kusworini (Handono et al., 2016) showed that administeration of 1 μg of IL-17A have been able to induce the formation of protective anti-IL-17A antibodies and improve immune response.
The development of elicit dose specific antigen immunotherapy with gradual selfantigen administration has been tried in multiple-sclerosis autoimmune models. The study used schwan cell self-antigens, the MBP (Myelin Basic Protein), and resulted in a significant reduction in proinflammatory cytokines and showed the return of tolerance mechanisms (Sakaguchi et al., 2001 ). Based on the success of Yuan et al's research, the question arises whether self-antigens dsDNA can be used as immunotherapy in autoimmune disease. The aim of this study is to explore the use of selfantigen dsDNA, as an inducer of immune system tolerance, in improving immune system regulation and restoring the mechanism of selfantigen tolerance in SLE disease. This research that will be conducted within two years is expected to observe the potential, effectiveness, and safety of escalating dose self-antigen dsDNA immunotherapy in pristane-induced lupus mice model. Remove the supernatant and add 300 μl of ethanol 70%. Turn the tube back and forth slowly and centrifuge at 13.500rpm for 1 minute. Ethanol is taken slowly without the pellets and tubes was reversed to dry, then add a DNA rehydration solution.
METHODS

Induction and treatment of pristane-induced lupus mice model
Balb/c female mice 6-8 weeks old and 20-30 grams body weight separated randomly to negative control group (healthy mice) and pristane induced lupus (PIL) mice group. PIL mice groups were injected 0.5 cc (782μg / ml) pristane intraperitoneally. Twelve weeks after the injection of pristane, the mice were evaluated for clinical and serological manifestations (anti-dsDNA levels). Mice with lupus signs or PIL mice were divided into four groups; positive control group: PIL mice without EDI dsDNA therapy, treatment A: PIL mice with EDI dsDNA therapy dose I (0.01 μg/ml, 0.1 μg/ml, 1 μg/ml) were administered once a week consecutively, treatment B: PIL mice with EDI dsDNA therapy dose dose II (0.1 μg/ml, 1 μg/ml, 10 μg/ml) were administered once a week consecutively and treatment C: PIL mice with EDI dsDNA therapy dose III (1 μg/ml, 10 μg/ml, 100 μg/ml) were administered once every week in consecutively..
Injection
The invivo-jetPEI reagent is dissolved in 5% glucose with sterile water solvent at halfvolume injection. Vortex slowly and spin down.
Add the solution entirely to the ds-DNA solution. Vortex slowly and spin down.
Incubation is performed for 15 minutes at room temperature until the solution becomes stable.
DsDNA is injected intraperitoneally according to the dose of each treatment group. Desensitization of dsDNA increase TGF-β level Our investigation was to assess the ability of the dsDNApeptide to increase TGF-β production.
Measurement of antibody levels against self antigen-dsDNA
Serum TGF-βlevels were slightly lower in K+ (261.02 ± 52.26) compared to K-(335.38 ± 27.80, p=0.14) . Serum TGF-βlevels in A (732.43 ± 98.69, p=0.03) were significantly higher and different compared to K+.The higher levels of serum TGF-β levels were found in B
(740.90 ± 25.3, p=0.079) compared to K+.
Serum TGF-β levels in C (382.25 ± 96.1, p= 0.24) were slightly higher but not significantly different compared to K+. 
